Skip Navigation

Edwin P. Alyea, MD

Medical Oncology

Make an Appointment
Watch Video


  • Associate Director, Stem Cell Transplantation
  • Director, Hematologic Malignancy Clinical Strategy
  • Institute Physician
  • Associate Professor of Medicine, Harvard Medical School


Clinical Interests

  • Leukemias
  • Multiple myeloma
  • Myelodysplasia
  • Stem cell/ bone marrow transplant

Diseases Treated

  • Allogeneic Stem Cell Transplant

Contact Information

  • Appointments617-632-5138 (new)
    617-632-6256 (follow-up)
  • Office Phone Number617-632-3903
  • Fax617-632-4422


Dr. Alyea received his MD from Duke University in 1989. He completed postgraduate training in internal medicine at Brigham and Women's Hospital, followed by a fellowship in medical oncology and hematology at DFCI and BWH. In 1996, he joined DFCI, where he currently is a member of the bone marrow transplant staff. His research centers on adoptive immunotherapy for the treatment of hematologic diseases.

Board Certification:

  • Hematology, 1997
  • Medical Oncology, 1995


  • Dana-Farber Cancer Institute, Hematology & Oncology


  • Brigham and Women's Hospital, Chief Medical Resident
  • Brigham and Women's Hospital, Internal Medicine
  • Brockton Veterans Administration Medical Center, Chief Medical Resident

Medical School:

  • Duke University School of Medicine


Adoptive Immunotherapy

Allogeneic bone marrow transplantation is curative for some patients with hematologic malignancies. Evidence suggests that the success of transplant is related not only to high doses of chemotherapy and radiation but also to the donor's immune system and whether it mediates an antileukemia effect, termed the graft-versus-leukemia (GVL) effect.Our group is currently exploring clinical methods to induce the GVL effect after bone marrow transplant. We have demonstrated that by infusing selected donor CD4+ lymphocytes, we can maintain the antileukemia activity while reducing the incidence of graft-versus-host disease. We are now conducting studies using donor dendritic cells in donor lymphocyte infusion (DLI) in an attempt to improve the response to DLI.We are also exploring nonmyeloablative transplantation strategies to establish a platform for adoptive immunotherapy. These "mini-transplants" allow allogeneic transplantation to be performed with much less toxicity - permitting patients of more advanced age or with other medical conditons to undergo transplantation. In addition, we are conducting studies focused on augmenting GVL after mini-transplantation.


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions